Other Vaccines - Taiwan

Taiwan

Highlights

The Other Vaccines market in Taiwan is estimated to generate a revenue of US$182.00m in 2024.
It is projected to experience a compound annual growth rate (CAGR 2024-2029) of 10.24%, leading to a market volume of US$296.40m by 2029.
When compared to other countries, United States is expected to generate the highest revenue of US$24.73bn in 2024.
Taiwan's Other Vaccines market is witnessing a surge in demand due to the government's proactive approach towards public health.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The demand for Other Vaccines in Taiwan has been increasing steadily over the past few years.

Customer preferences: The Taiwanese population has become increasingly health-conscious, leading to a growing demand for preventive healthcare measures such as vaccinations. Additionally, the recent outbreak of COVID-19 has further highlighted the importance of vaccines and has increased public awareness and acceptance of vaccination programs.

Trends in the market: Taiwan has a well-established healthcare system, with the government playing a significant role in regulating and funding healthcare services. The government has been actively promoting vaccination programs, particularly for children and the elderly, which has contributed to the growth of the Other Vaccines market. In addition, the increasing prevalence of infectious diseases such as influenza and hepatitis has also driven demand for vaccines.

Local special circumstances: Taiwan is a densely populated country with a high population density in urban areas, making it more susceptible to disease outbreaks. The government has been proactive in addressing this issue by implementing vaccination programs and regulations to improve public health. Additionally, Taiwan has a large elderly population, which is more vulnerable to infectious diseases and requires regular vaccination.

Underlying macroeconomic factors: Taiwan has a strong economy with a high level of government investment in healthcare. The government has been increasing its healthcare budget in recent years, which has contributed to the growth of the Other Vaccines market. Furthermore, Taiwan has a highly educated population with a high level of healthcare literacy, which has also driven demand for vaccination programs. Overall, the combination of a strong economy, government investment in healthcare, and a health-conscious population has created a favorable environment for the growth of the Other Vaccines market in Taiwan.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.